# Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"

> **NCT02221284** · — · COMPLETED · sponsor: **Takeda** · enrollment: 964 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin

## Key facts

- **NCT ID:** NCT02221284
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-30
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-06-30
- **Target enrollment:** 964 (ACTUAL)
- **Last updated:** 2019-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221284, "Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02221284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*